Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + Eribulin in Advanced Breast Cancer
NCT01427933Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2011
- Primary completion
- Sep 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in breast cancer, sponsored by Eli Lilly and Company. Started Nov 2011; status: completed.
02
Drugs
ramucirumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01427933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01427933.